It is difficult to say what is impossible, |
The Acid Maltase Deficiency Association, A
M D A, was formed to assist in funding |
Updated
March 2,
2009
IPA Statement: The End of Myozyme Supply Restrictions (new)
Pompe
Program Update from Genzyme
(new)
Genzyme Receives Complete Response Letter from FDA on Lumizyme Application (new)
European Authorities Approve Larger-Scale Production of Genzyme's Myozyme (new)
Genzyme Receives Positive Opinion on
Myozyme (2000L) from CHMP in Europe
(new)
Myozyme
Supply Update January 2009 from Genzyme--Global version
Myozyme Supply
Update January 2009 from Genzyme--United States version
EMEA Press Release concerning Myozyme supply situation--January 16, 2009
Guidance to the
Pompe Community on the Management of
Myozyme Supply
develpoed
by the Myozyme Stakeholders Working Group
This
guidance is being distributed to all treating physicians
worldwide except those in the European Union (EU).
Separate guidance will be sent to European healthcare professionals in
accordance with the requirements of the
European Medicines Agency (EMEA); we expect that document to be
distributed on or before 16th January 2009
and we would hope to publish it on this website soon afterwards.
IPA Statement Regarding the Management of
Myozyme Supply--advice to Patient Groups
IPA Statement Regarding the Management of
Myozyme Supply--advice to Pompe Patients
AMDA Statement Regarding the Management of "Myozyme" supply
Frequently Asked Questions complied by the IPA
Thank you, Donna, for all of your help!
© AMDA, Acid
Maltase Deficiency Association, Inc. 1997
P.O. Box 700248 · San Antonio, Texas 78270-0248
Phone: (210) 494-6144
Fax: (210) 490-7161